---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-274053"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:12:37.024134+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Bio Q3 2023 cash $164.4M; CABA-201 data expected H1 2024; IND clearances for SSc and gMG

## Summary
- Cash, cash equivalents and short-term investments of $164.4M as of Sept 30, 2023, up from $106.5M at Dec 31, 2022.
- R&D expenses $13.8M (vs $8.2M in Q3 2022); G&A expenses $4.9M (vs $3.6M).
- Initial clinical data from CABA-201 Phase 1/2 trials in lupus and/or myositis expected in first half of 2024.
- IND clearances received for CABA-201 in systemic sclerosis (SSc) and generalized myasthenia gravis (gMG).
- WuXi ATU selected as GMP manufacturing partner; Oxford Biomedica as lentiviral vector supplier for CABA-201.

## SEC filing metadata
- accession: 0001193125-23-274053
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000119312523274053/0001193125-23-274053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000119312523274053/d581425d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-274053
- JSON: https://secwatch.observer/filing/0001193125-23-274053.json
- Plain text: https://secwatch.observer/filing/0001193125-23-274053.txt

## Key facts
- Earnings Releases
  Cabaletta Bio, Inc. reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 9, 2023, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759138/000119312523274053/0001193125-23-274053-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.